The Brazilian Health Regulatory Agency (ANVISA) approved Probiokid for use in infants and children aged 3 months to 36 months.
Lallemand Health Solutions (Toulouse, France) announced that its Probiokid probiotic ingredient has gained approval in Brazil for use in infants and children. The Brazilian Health Regulatory Agency (ANVISA) approved Probiokid for use in infants and children aged 3 months to 36 months in the Brazilian market. Numerous pediatric studies have shown that Probiokid helps support immune and gut health.
Probiokid is a combination of three Lallemand probiotic strains: L. helveticus Rosell-52, B. infantis Rosell-33, and B. bifidum Rosell-71. Probiokid already has Generally Recognized as Safe (GRAS) status in the U.S. “for non-exempt infant formula, from birth,” and is also allowed in infant foods in China.
In a press release, Solange Henoud, vice president, regulatory and compliance, Lallemand Health Solutions, stated, “Our product, supported by decades of scientific, marketing, and regulatory accomplishments, has achieved the almost impossible nowadays: getting approval in Brazil. It is the first one of this year. It’s been a while since anyone from the industry has made it this far, but with a documented product such as Probiokid, with its extensive marketing journey and various regulatory acknowledgements across the globe for infants and children, we felt confident.”
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.